However, HER2-directed therapies, such as trastuzumab, pertuzumab, and trastuzumab deruxtecan, have been shown to improve survival outcomes for patients at all stages of HER2-positive breast cancer [1, 6, 8–10]. This evidence concerns the gene ERBB2 and breast cancer.